Measles, mumps and rubella vaccine 12 months after hematopoietic stem cell transplantation

• Autor(a) principal: Randi, Bruno Azevedo
• Data de Publicação: 2023
• Outros Autores: Fernandes, Eder Gatti, Higashino, Hermes Ryoiti, Lopes, Marta Heloisa, Rocha, Vanderson Geraldo, Costa, Silvia Figueiredo, Sartori, Ana Marli Christovam
• Tipo de documento: Artigo
• Idioma: eng
• Título da fonte: Revista do Instituto de Medicina Tropical de São Paulo
• Texto Completo: https://www.revistas.usp.br/rimtsp/article/view/209702
• topic: Measles-mumps-rubella vaccine; MMR vaccine; Hematopoietic stem cell transplantation; Measles; Transplantation

The measles, mumps and rubella (MMR) vaccine is usually recommended from 24 months after a hematopoietic stem cell transplant (HSCT). Some authors have demonstrated that the MMR vaccination can be safe from 12 months post-HSCT in non-immunosuppressed patients, as recommended by the Brazilian National Immunization Program/Ministry of Health, since 2006. The objectives of this study were to evaluate when patients received MMR vaccine after an HSCT in our care service and if there were reports of any side effects. We retrospectively reviewed the records of HSCT recipients who received at least one MMR dose in our care service, a quaternary teaching hospital in Sao Paulo city, Brazil, from 2017 to 2021. We identified 82 patients: 75.6% (90.1% in the autologous group and 45.1% in the allogeneic group) were vaccinated before 23 months post-transplantation. None reported side effects following the vaccination. Our data support that the MMR vaccination is safe from 12 to 23 months after HSCT.